2. Search Result
Search Result
Results for "

ejection fraction

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-145581
    Mitiperstat

    AZD4831

    		 Glutathione Peroxidase Cytochrome P450 Cardiovascular Disease Inflammation/Immunology
    Mitiperstat (AZD4831) is an effective oral inhibitor of myeloperoxidase (MPO). Mitiperstat inhibits MPO and thyroid peroxidase (TPO) with IC50s of 1.5 nM and 0.69 μM. Mitiperstat exhibits a weak inhibitory activity against CYP3A4 with an IC50 of 6 μM. Mitiperstat can reduce inflammation and improve microvascular function, and it can be used in studies related to heart failure, preserved or mildly reduced ejection fraction, non-alcoholic fatty liver disease, and chronic obstructive pulmonary disease .
    Mitiperstat
  • HY-109136
    Runcaciguat
    1 Publications Verification

    BAY 1101042

    		 Guanylate Cyclase Cardiovascular Disease Metabolic Disease
    Runcaciguat (BAY 1101042) is a selective, orally active, allosteric activator of soluble guanylate cyclase (sGC) that specifically targets its oxidized and heme-free form. Runcaciguat binds to sGC in a histidine-dependent manner and restores cyclic guanosine monophosphate (cGMP) production under oxidative stress, independent of nitric oxide (NO) or heme. Runcaciguat exhibits renoprotective and cardioprotective activities, such as reduced proteinuria and improved renal function. Runcaciguat is primarily being studied in chronic kidney disease (CKD) associated with hypertension, diabetes, and metabolic disorders, as well as potential cardiovascular indications such as heart failure with preserved ejection fraction (HFpEF) .
    Runcaciguat
  • HY-157538
    PDK4-IN-2

    		PDHK Cardiovascular Disease
    PDK4-IN-2 (compound 8) is a pyruvate dehydrogenase kinase 4 (PDK4) inhibitor with an IC50 of 46 µM. PDK4-IN-2 improves ejection fraction of failing hearts by regulating bioenergetics via activation of the tricarboxylic acid cycle .
    PDK4-IN-2
  • HY-176233
    Transthyretin-IN-4

    		Transthyretin (TTR) Cardiovascular Disease
    Transthyretin-IN-4 (Compound B26) is a bivalent inhibitor of transthyretin (TTR) amyloidosis (bIC50: 0.09 µM, pIC50: 1.4 µM). Transthyretin-IN-4 is used in the study of fatal heart failure with preserved ejection fraction (HFpEF) and fatal arrhythmias .
    Transthyretin-IN-4
  • HY-W145695
    Chitoheptaose

    		Biochemical Assay Reagents Inflammation/Immunology
    Chitoheptaose is a chitosan oligosaccharide. Chitoheptaose is capable of extracting exoskeletons from crustaceans, such as the shells of crabs, shrimp and lobsters. Chitoheptaose has antioxidant, anti-inflammatory and anti-apoptotic activities and can be used in the study of myocarditis. Chitoheptaose has cardioprotective effects and improves cardiac parameters (left ventricular internal size, end-systolic and end-diastolic, ejection fraction and shortening fraction), inflammatory cytokines (IL-1β) in vanishing models .
    Chitoheptaose
  • HY-P1428A
    RFRP-1(human) TFA

    		Neuropeptide Y Receptor Cardiovascular Disease
    RFRP-1(human) TFA is a potent endogenous NPFF receptor agonist (EC50 values are 0.0011 and 29 nM for NPFF2 and NPFF1, respectively). Attenuates contractile function of isolated rat and rabbit cardiac myocytes. Reduces heart rate, stroke volume, ejection fraction and cardiac output, and increases plasma prolactin levels in rats.
    RFRP-1(human) TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: